CClinicalTrials.gg
CompletedNCT00559819ALCDriveUpdated Dec 14, 2022

Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving

A Phase 3 interventional study of placebo and Alcohol in Driving, Intoxication and Impairment, sponsored by Rush University Medical Center. Completed at 1 site in United States. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-14.

Sponsored by Rush University Medical Center · Phase 3, Interventional, and Diagnostic

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Study summary

The proposed study will validate and determine sensitivity of our new driving simulator, created to evaluate driving ability in a related study to show similar driving performance between patients on chronic opioid treatment and a control group. Although the commercial version of the simulator has been validated for certain populations and certain measures, these require re-calibration for our own clinical study. The investigators propose a prospective randomized clinical trial to evaluate driving skills under alcohol consumption using a driving simulator. Two groups of study subjects will be utilized, with the majority (80%) receiving alcohol and placebo at different times. A smaller set of study subjects (20%) will be given placebo on both trials to evaluate learning effects and placebo blinding effectiveness. Each group will take the driving test at three time points: once as a baseline at the beginning of the study, once after the 1st dosing of the placebo and again after dosing two of the alcohol or placebo beverage. This information will allow us to evaluate driving ability under other potentially impairing conditions such as opioid usage.

Read the detailed description

Subjects will be recruited via discreet flyers distributed around the Rush University Medical Campus. Subjects will be scheduled so that a maximum of 6 participants are evaluated on the same day. Some evaluation days may fall on the weekend. Study duration is estimated at 4-5 hours, and at the completion the subjects will be driven to their respective residences.

Upon arrival subjects will complete questionnaires which contain demographic information and measures to evaluate possible alcohol abuse issues. All subjects will be given a short driving simulator practice and then the baseline simulator trial. Subjects will be randomized into two groups as part of a study, with an 80% probability of selection for group A and a 20% probability of selection for Group P. Group P will only be given placebos so that any learning effects can be estimated. In addition to the baseline, both groups will take the full driving test two additional times each preceded by an alcohol or placebo dosing. Of these two trials only on Trial#2 of Group A is alcohol given. Both groups will receiver placebo on simulator Trial #1.

Alcohol trial (Group A only):

The alcohol dose will consist of a 40% alcohol (vodka) liquor in a beverage containing 2 parts orange juice and 1 part liquor. The exact amount/volume of alcohol will be determined based on factors such as weight and sex so as to reach a peak BAC of 0.08%.

The primary contrast of interest is the comparison between the placebo and the alcohol dosed driving simulation trials. Analyses will take place with general linear models framework, using "Proc Mixed" to model the repeated measures design and produce accurate estimate of the pre-planned comparisons as well as main effects and longitudinal estimates. Various outcome variables that measure driving ability will be used, the three primary measures being: a measure of weaving (Standard Deviation of Lateral Deviation), Reaction Time (RT) to unexpected stimuli, and number of accidents. The placebo, Group P, will be evaluated to estimate the effect of learning and to estimate the effectiveness of the placebo sham.

02

Conditions studied

  • Driving
  • Intoxication
  • Impairment
  • Alcohol Impaired Driving

Keywords

  • Alcohol
  • Driving
  • Impairment
03

In context

Lead sponsor

Rush University Medical Center is the lead sponsor of 394 studies on the registry; 61 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 25 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Legal drinking age (=> 21).
  2. Moderate alcohol consumption

    • Defined as: at least 1 unit per week but less than 20 units per week. (unit = 12 oz. beer or equivalent).
  3. Current driver's license.
  4. Subjects can understand and communicate in English.

Exclusion criteria

Exclusion Criteria:

  1. Known alcoholic or drug abuser.
  2. Alcohol naïve.
  3. Use of medications that may be aggravated (or contraindicated) by alcohol.
  4. Pregnant or breast feeding.
  5. Younger than 21 years or older than 80 years.
05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Alcohol

    Alcohol

    Drug: Alcohol

  • Placebo comparator
    Placebo

    Orange juice

    Drug: placebo

Interventions

  • Drugplacebo

    Placebo (orange juice), same volume as alcohol

    Also known as: Orange Juice

  • DrugAlcohol

    Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%

    Also known as: Vodka

06

What researchers measure

Primary outcomes

  1. Weaving (Standard Deviation of Lateral Deviation)

    Time frame: 6 h

Secondary outcomes

  1. Reaction Time (RT) to unexpected stimuli, and number of accidents

    Time frame: 6 h

07

Study locations

1 site
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00559819
Lead sponsor
Rush University Medical Center
Responsible party
Mario Moric (Research Coordinator, Rush University Medical Center) — Principal investigator
First posted
Nov 16, 2007
Start date
Feb 2008
Primary completion
Mar 2022
Completion
Jul 2022
Last update
Dec 14, 2022

Study contacts

Asokumar Buvanendran, MD
study director · Rush University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion